- Institute of Environmental Science and Research Limited. Pertussis Report: July to September 2015. Available at http://www.surv.esr.cri.nz/surveillance/PertussisRpt.php Accessed March 2017
- Ministry of Health. Immunisation Handbook 2014 – 3rd edition, April 2016. Available at http://www.health.govt.nz/publication/immunisation-handbook-2014-3rd-edn Accessed March 2017
- Mattoo S and Cherry JD. Clin Microbiol Rev. 2005;18:326–382.
- Miller E et al. Commun Dis Public Health. 2000;3:132–134.
- Zepp F et al. Lancet Infect Dis. 2011;11:5 57– 570.
- Wendelboe AM et al. Pediatr Dis. 2007;26:293–99.
- Wendelboe AM et al. Pediatr Infect Dis J. 2005;24 (Supp 5):S58–S61.
- Boostrix Data Sheet, GSK New Zealand; May 2016. Available at http://www.medsafe.govt.nz/profs/Datasheet/b/Boostrixinj.pdf Accessed 9 March 2017
- Centers for Disease Control and Prevention. Pertussis (Whooping Cough), Prevention: Adults. Available at https://www.cdc.gov/pertussis/about/prevention/adults.html Accessed 9 March 2017
- Forsyth KD et al. Vaccine. 2007;25:2634-42.
Boostrix® (combined diphtheria, tetanus, and acellular pertussis (dTpa or Tdap) vaccine) is available as an injection. Boostrix is for booster immunisation of people aged 4 years and older against diphtheria, tetanus, and pertussis (whooping cough). Boostrix is government funded for 11 year olds as part of the national immunisation schedule, and for pregnant women between 28 and 38 weeks gestation (Category B1). It is also available as a private-purchase prescription medicine – you will have to pay normal doctor’s visit fees and a prescription charge. A trained pharmacist can also administer Boostrix to a person aged 18 years and older. A 0.5 mL dose contains not less than 2.5 LfU of diphtheria toxoid, not less than 5 LfU of tetanus toxoid, and three purified antigens of Bordetella pertussis (8mcg of pertussis toxoid, 8 mcg of filamentous haemagglutinin, and 2.5 mcg of 69 kDa outer membrane protein). Tell your healthcare professional if you are pregnant or breastfeeding to be informed of the benefits and risks of Boostrix. Boostrix should not be administered if you or your child are hypersensitive to any component of this vaccine or similar vaccines, or have had swelling or disease of the brain after previous pertussis (whooping cough) vaccination, or any problems with blood clotting or the nervous system (such as spasms, epilepsy and brain disease) after earlier immunisation against diphtheria or tetanus. Common side effects include fever, irritability, fatigue, malaise, headache, loss of appetite, vomiting and diarrhoea, and local reactions such as pain, redness, bruising, itching, or swelling at the injection site. If you or your child have side effects, see your doctor, pharmacist, or health professional. Additional Consumer Medicine Information for Boostrix is available at www.medsafe.govt.nz. Ask your doctor if Boostrix is right for you or your child. Boostrix is a registered trade mark of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland.
Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.